Biotechnology News and Research RSS Feed - Biotechnology News and Research

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array BioPharma Inc. today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015. [More]
Soligenix signs $10M  equity purchase agreement with accredited institutional investors

Soligenix signs $10M equity purchase agreement with accredited institutional investors

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has entered into a $10 million equity purchase agreement with accredited institutional investors, Kodiak Capital Group, LLC, Kingsbrook Opportunities Master Fund LP and River North Equity, LLC. [More]
Twi Biotechnology gets notice of patent allowance covering use of AC-201 drug in diabetes treatment

Twi Biotechnology gets notice of patent allowance covering use of AC-201 drug in diabetes treatment

TAIPEI, Aug. 3, 2015 /PRNewswire/ -- TWi Biotechnology, Inc., today announced that it has received Notices of Allowance for AC-201, TWi Biotechnology's lead drug candidate, from the European Patent Office and the Patent Office of the Russian Federation for patent applications numbered 11766702.2-1460 and 2012147449, respectively. [More]
Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic breast cancer

Eisai, Halozyme partner to evaluate eribulin and PEGPH20 in HER2-negative metastatic breast cancer

Eisai Inc. announced today that its parent company Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Halozyme Therapeutics, Inc. (Headquarters: San Diego, California, President and CEO: Dr. Helen Torley) have signed a clinical collaboration agreement to evaluate Eisai's agent eribulin mesylate (brand name: Halaven, "eribulin") in combination with Halozyme's investigational drug PEGPH20 (PEGylated recombinant human hyaluronidase) in first line HER2-negative metastatic breast cancer. [More]

Derek Muhs selected for Excellence in Branding and Marketing

Health Care Management China today announced that Co-Founder and Vice Chairman Derek Muhs has been nominated for Excellence in Branding and Marketing by the Awards Jury of the 6th Annual CMO ASIA AWARDS, to be held in Singapore on August 11, 2015. [More]
IDIBELL licenses a tool to Oxford Immunotec to improve efficiency of kidney transplants, prevent graft rejection

IDIBELL licenses a tool to Oxford Immunotec to improve efficiency of kidney transplants, prevent graft rejection

The Bellvitge Biomedical Research Institute has licensed to the company Oxford Immunotec, a technology to measure the secretion of anti-HLA antibodies from memory B cells to improve the efficiency of kidney transplants and prevent rejection of graft. [More]
Novel 3D human skin tissue model could help detect presence of known skin sensitizers in medical device extracts

Novel 3D human skin tissue model could help detect presence of known skin sensitizers in medical device extracts

New research shows that exposing a 3D human skin tissue model to extracts of medical device materials can detect the presence of sensitizers known to cause an allergic response on contact in some individuals. Conventional skin sensitization testing of medical devices relies on animal testing, whereas human skin models could replace animal methods, according to an article in the new journal Applied In Vitro Toxicology, a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. [More]
Balancing cellular aging and cancer risk through biotechnology

Balancing cellular aging and cancer risk through biotechnology

In a way, trying to repair age-related heart damage and trying to fight cancer are opposite problems. Your heart cells' ability to regenerate themselves and proliferate into new, young cells degrades as you get older. [More]
Low blood level of 4 proteins can help diabetics protect against immune attack

Low blood level of 4 proteins can help diabetics protect against immune attack

Patients with type 1 diabetes have significantly lower blood levels of four proteins that help protect their tissue from attack by their immune system, scientists report. [More]
World Health Organization recognizes unique pharmacological nature of Can-Fite's CF101, grants new generic name

World Health Organization recognizes unique pharmacological nature of Can-Fite's CF101, grants new generic name

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced that the World Health Organization's International Nonproprietary Name group has accepted the proposed generic name "piclidenoson" for its lead drug candidate, CF101. [More]
PDL BioPharma signs revenue interest assignment agreement with ARIAD Pharmaceuticals

PDL BioPharma signs revenue interest assignment agreement with ARIAD Pharmaceuticals

PDL BioPharma, Inc. today announced that it has entered into a revenue interest assignment agreement (the "Agreement") in which it has agreed to provide ARIAD Pharmaceuticals, Inc. with up to $200 million in revenue interest financing in exchange for royalties on the net revenues of Iclusig (ponatinib). [More]
New polymer gel could help create swallowable devices for ultra-long drug delivery

New polymer gel could help create swallowable devices for ultra-long drug delivery

Medical devices designed to reside in the stomach have a variety of applications, including prolonged drug delivery, electronic monitoring, and weight-loss intervention. However, these devices, often created with nondegradable elastic polymers, bear an inherent risk of intestinal obstruction as a result of accidental fracture or migration. As such, they are usually designed to remain in the stomach for a limited time. [More]
AMSBIO launches CellMax™ Cell Pellet Slides

AMSBIO launches CellMax™ Cell Pellet Slides

AMSBIO announces the launch of CellMax™ - a new range of high quality, consistent and affordable cell line FFPE slides. [More]

United Therapeutics’ revenues increase by $24.4 million in second quarter 2015

United Therapeutics Corporation today announced its financial results for the second quarter ended June 30, 2015. "Orenitram sales grew nearly 300% as compared to the second quarter of 2014 when the product was first launched," said Roger Jeffs, Ph.D., United Therapeutics' President and Co-Chief Executive Officer. [More]
German life sciences entrepreneurs granted option to develop Aeterna Zentaris’ oral allogenic tumor vaccine technology

German life sciences entrepreneurs granted option to develop Aeterna Zentaris’ oral allogenic tumor vaccine technology

Aeterna Zentaris Inc. today announced that it has granted to German life sciences entrepreneurs with a proven track-record of funding the development and commercialization of biotechnology, an option to license the Company's live recombinant oral allogenic tumor vaccine technology, including AEZS-120, the most advanced product candidate for prostate cancer which is ready to enter a Phase 1 clinical trial. [More]
Champions Oncology's revenue increases 32% to $3.2 million in fourth quarter 2015

Champions Oncology's revenue increases 32% to $3.2 million in fourth quarter 2015

Champions Oncology, Inc., engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the year ended April 30, 2015. [More]
Innovative approach to treating AAT deficiency

Innovative approach to treating AAT deficiency

Researchers have demonstrated the feasibility of delivering an RNA that encodes for the protein alpha-1-antitrypsin (AAT)--which is missing or nonfunctional in the genetic disorder AAT deficiency--into cells in the laboratory, enabling the cells to produce highly functional AAT. [More]

FDA grants Fast Track Designation to TxCell’s Ovasave for treatment of Crohn’s disease

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has granted Fast Track Designation to TxCell’s lead product Ovasave for the treatment of moderate to severe Crohn’s disease. [More]
Study reveals impact of patient navigator program on no-show rates for cervical cancer screening

Study reveals impact of patient navigator program on no-show rates for cervical cancer screening

Researchers at Harvard Medical School and Brigham and Women's Hospital reported a 20% decline in the rate of missed appointments for cervical cancer evaluation following a Pap smear when a patient navigator program was initiated at the referral center. [More]
Wayne State's faculty selected for Aspen Health Innovators Fellowship

Wayne State's faculty selected for Aspen Health Innovators Fellowship

The Washington, D.C.-based educational and policy studies organization The Aspen Institute has selected Wayne State University School of Medicine's Patrick Hines, M.D., Ph.D., associate professor of Physiology and an assistant professor of Pediatric Critical Care Medicine, one of only 20 health care leaders in the country for the inaugural class of its Health Innovators Fellowship. [More]
Advertisement
Advertisement